Topic: antibiotic-resistant bacteria
Governments around the world continue to sound alarm bells over a potential antimicrobial resistance “apocalypse.”
German officials put up the money as part of their decision to join U.S. and U.K. authorities in the CARB-X partnership.
Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.
The week’s biotech news included insight into how circulating tumor cells form metastases and how bacteria evade copper antibiotics.
Government officials floated the idea in a report setting out how the U.K. plans to tackle the threat posed by drug-resistant bacteria.
The fund funneled around $16 million (€14 million) into the startups to support research into antibiotics and prophylactic vaccines.
Just over a year after its first-round financing, Locus Bio has signed up J&J as its first big pharma partner, pocketing a $20 million upfront fee.
With Xerava, Tetraphase Pharmaceuticals used technology pioneered at Harvard University to create a tetracycline that can overcome resistant pathogens.
RedHill Biopharma’s antibiotic cocktail RHB-105 bested an amoxicillin combination in patients with H. pylori infection, topline phase 3 data show.
Roivant has licensed a midstage drug from South Korea’s Intron Bio that it says could be transformative in the fight against resistant bacteria.